Impact of Leflunomide Versus Biologic Agents on the Costs of Care for Rheumatoid Arthritis in a Managed Care PopulationByDaniel A. Ollendorf, MPH,Anna N. Peterson, BA,Joseph Doyle, RPh, MBA,Daniel M. Huse, MAMay 1st 2002
Use of Managed Care Claims Data in the Risk Assessment of Venous Thromboembolism in OutpatientsByMason W. Russell, MAPE,Douglas C. A. Taylor, MBA,Gordon Cummins, MS,Daniel M. Huse, MAJanuary 1st 2002
Outpatient Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin: An Economic EvaluationByDaniel M. Huse, MA,Gordon Cummins, MS,Douglas C. A. Taylor, MBA,Mason W. Russell, MAPEJanuary 1st 2002
Anti-inflammatory Therapy Reduces Total Costs of Asthma Care Compared with Bronchodilation: The Asthma Outcomes RegistryByDaniel M. Huse, MA,Mason W. Russell, MAPE,Scott T. Weiss, MD, MS,Stuart C. Hartz, ScDSeptember 1st 2000
